Online citations, reference lists, and bibliographies.
← Back to Search

Adaptation Of A Chemosensitivity Assay To Accurately Assess Pemetrexed In Ex Vivo Cultures Of Lung Cancer

Sarah L. Suchy, R. Landreneau, M. Schuchert, D. Wang, Paul R. Ervin, Jr., S. Brower
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose: Pemetrexed is the only FDA approved treatment for mesothelioma and is a second line agent for treatment of non-small cell lung carcinoma (NSCLC). Pemetrexed is inhibited by folate and its analogs, which are components of many culture media, making it challenging to study pemetrexed in vitro. In order to accurately evaluate pemetrexed’s effects in vitro, the protocol for a standard chemosensitivity assay, the ChemoFx drug response marker, had to be modified. Experimental Design: Novel rinse and media change steps were assessed and then added to the assay protocol in order to observe pemetrexed activity. The intraday and interday stability of pemetrexed were also established under the adapted protocol. Then, the modified protocol was used to examine pemetrexed in 65 ex vivo lung cancer specimens. Results: Substituting 5% RPMI + EGF for BEGM allowed pemetrexed to exert its anticancer activity in the ChemoFx DRM. ChemoFx classified 6.2% of the lung specimens as responsive, 9.2% as intermediate responsive and 84.6% as non-responsive to pemetrexed. Conclusions: Adapting the ChemoFx protocol allowed for the accurate evaluation of pemetrexed anticancer activity in ex vivo lung specimens. ChemoFx evaluation may provide an indication of a patient’s clinical response to the drug prior to pemetrexed treatment. Having this information when treatment options are being considered could avoid wasted time, unnecessary costs and needless side effects that are the result of an inappropriate chemotherapy regimen.
This paper references
10.1136/bmj.325.7358.269
Efficacy, safety, and cost of new anticancer drugs
S. Garattini (2002)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Biochemical pharmacology of pemetrexed.
A. Calvert (2004)
Vitamin B12 in Cell Culture
D R Conrad
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
Methods for predicting a cancer patient's response to antifolate chemotherapy description/claims
S L Suchy
10.1517/14656566.5.11.2381
Clinical-economic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients
A. Messori (2004)
10.1634/THEONCOLOGIST.12-7-808
Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
S. Chattopadhyay (2007)
Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
J. Worzalla (1998)
Secondline treatment for advanced-stage non-small-cell lung cancer: current and future options
C Ho (2006)
10.1200/JCO.1999.17.4.1194
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
J. Rusthoven (1999)
10.3816/CLC.2004.S.003
Pharmacology and mechanism of action of pemetrexed.
A. Adjei (2004)
Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Z. Mi (2008)
10.2486/INDHEALTH.MS1147
Malignant mesothelioma: a clinical study of 238 cases.
Steven E. Haber (2011)
10.1002/cncr.23058
The value of medical interventions for lung cancer in the elderly
Rebecca Woodward (2007)
10.1136/BMJ.325.7375.1302
Sexual health services need wider approach
L. Bacon (2002)
10.1001/JAMA.280.23.1992-A
Cost-effectiveness analyses of statistically ineffective treatments.
S. Trippoli (1998)
10.3322/canjclin.56.2.106
Cancer Statistics, 2006
A. Jemal (2006)
10.1186/1471-2407-8-216
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F. Russo (2008)
Available from URL: www
10.1158/1078-0432.CCR-04-2013
Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer
Z. Hu (2005)
10.2174/092986707780831041
Co-treatment with copper compounds dramatically decreases toxicities observed with cisplatin cancer therapy and the anticancer efficacy of some copper chelates supports the conclusion that copper chelate therapy may be markedly more effective and less toxic than cisplatin therapy.
J. Sorenson (2007)
10.1016/j.lungcan.2009.07.011
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
G. Scagliotti (2010)
Investigators of Italian Pemetrexed Monotherapy of NSCLC Group. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo (2008)
10.1038/sj.bjc.6603995
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
K. M. Li (2007)
10.1258/JRSM.98.10.455
Mesothelioma: time to take stock.
C. Tan (2005)
Available at: www. sigmaaldrich.com/catalog/ProductDetail.do?D7=0& N5=SEARCH_CONCAT_PNO%7CBRAND_KEY &N4=R1145%7CSIGMA&N25=0&QS=ON&F=SP EC
10.1200/JCO.2003.12.004
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
W. Weber (2003)
10.1158/1078-0432.CCR-07-5143
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Y. Ohe (2008)
10.1200/JCO.2008.19.1650
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
E. Smit (2009)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
R. Zhao (2005)
10.1007/978-1-59745-339-4_6
The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy.
S. Brower (2008)
10.1634/THEONCOLOGIST.10-6-363
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
M. Cohen (2005)
10.1038/sj.bjc.6603321
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours
K. Nakagawa (2006)
10.1016/S0093-7754(02)70040-7
Molecular, biochemical, and cellular pharmacology of pemetrexed.
I. Goldman (2002)
10.1002/jso.21787
Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
D. Baratti (2011)
10.1634/THEONCOLOGIST.10-90003-1
Optimizing first-line treatment options for patients with advanced NSCLC.
H. Wakelee (2005)
10.1007/s11864-008-0071-3
Systemic Treatments for Mesothelioma: Standard and Novel
H. Kindler (2008)
National Cancer Institute of Canada Clinical Trials Group. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
JJ Rusthoven (1999)
10.1016/j.ajog.2010.01.059
Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer.
T. Herzog (2010)
10.1111/J.1525-1438.2006.00301.X
Progression‐free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay
H. Gallion (2006)
10.3816/CLC.2006.S.003
Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
C. Ho (2006)
10.1038/sj.bjc.6600673
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
S. Tomek (2003)
10.1016/J.CLINTHERA.2005.09.010
Pemetrexed: a multitargeted antifolate.
K. D. Rollins (2005)
10.1200/JCO.2004.08.163
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
N. Hanna (2004)
10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO;2-V
Folate depletion increases sensitivity of solid tumor cell lines to 5‐fluorouracil and antifolates
H. Backus (2000)
10.1186/1756-9966-29-38
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
G. Zhang (2010)
10.1017/S1462399409000969
Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.
R. Zhao (2009)
10.6004/JNCCN.2008.0024
Neoadjuvant chemotherapy in stage III NSCLC.
J. Allen (2008)
56:106-30; PMID:16514137; http://dx.doi. org/10.3322/canjclin.56.2.106
A Jemal (2006)
Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness.
A. Messori (2002)
10.2217/14796694.1.6.733
Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
B. Solomon (2005)
10.1021/mp900296k
Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
C. Müller (2010)
10.1016/J.LUNGCAN.2007.10.008
Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
A. Bearz (2008)
10.1200/JCO.2010.28.8126
The evolving role of histology in the management of advanced non-small-cell lung cancer.
C. Langer (2010)
10.2174/092986710791959710
Will antiangiogenic agents be a future for mesothelioma therapy?
C. Belli (2010)
10.1097/JTO.0b013e3181d86ea9
Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma: A Review and Case Report
C. Bech (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar